Instinct Brothers, a Japanese-based regenerative medicine and stem cell technology company, and special purpose acquisition company Relativity Acquisition entered into a merger agreement, the companies said Tuesday.
Under the terms of the agreement, the companies said Relativity will acquire all outstanding shares of Instinct Brothers, and it will become a wholly-owned unit of Relativity.
Upon closing, the combined company will operate as Instinct Bio Technical and plans to list on the Nasdaq exchange under the 'BIOT' ticker.
The merger values the combined entity at about $242 million and is expected to close in Q3, subject to shareholder approval and other customary conditions, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.